

Depressive Symptoms, Health Behaviors, and Subsequent Inflammation in Patients With Coronary Heart Disease: Prospective Findings From the Heart and Soul Study

Hester E. Duivis, M.Sc.

Peter de Jonge, Ph.D.

Brenda W. Penninx, Ph.D.

Bee Ya Na, M.P.H.

Beth E. Cohen, M.D., M.A.S.

Mary A. Whooley, M.D.

Objective: Depression has been associated with inflammation in patients with coronary heart disease. However, it is uncertain whether depressive symptoms lead to inflammation or vice versa.

Method: The authors evaluated 667 outpatients with established coronary heart disease from the Heart and Soul Study. Depressive symptoms were assessed annually with the 9-item Patient Health Questionnaire. Participants were categorized as having no significant depressive symptoms (score below 10 at all interviews), depressive symptoms (score of 10 or higher) at one interview, or depressive symptoms at two or more interviews. At baseline and 5-year follow-up, fasting blood samples were collected to measure three inflammatory biomarkers: fibrinogen, interleukin-6 (IL-6), and high-sensitivity C-reactive protein (hsCRP).

Results: Of the 667 participants, 443 had no depressive symptoms, 86 had depressive symptoms at one assessment, and

138 had depressive symptoms at two or more annual assessments. Across the three groups, greater depressive symptoms were associated with higher subsequent log-transformed levels of IL-6 and hsCRP, and the association with higher fibrinogen levels approached significance. Baseline inflammation did not predict subsequent depressive symptoms. The association of depressive symptoms with subsequent inflammation levels was eliminated after adjustment for health behaviors associated with depression—physical inactivity, smoking, and higher body mass index.

Conclusions: Depressive symptoms predicted higher IL-6 and hsCRP levels among outpatients with coronary heart disease, but higher inflammation levels did not predict subsequent depressive symptoms. The association between depressive symptoms and inflammation was no longer significant after adjustment for health behaviors, which suggests these behaviors may mediate depressive effects.

(*Am J Psychiatry* 2011; 168:913–920)

Depression is common in patients with cardiac disease, with prevalence rates nearly three times as high as in the general population (1, 2). Depression is also associated with worse cardiac prognosis and greater mortality (3). However, there is still considerable debate regarding how depression might contribute to a worse cardiac prognosis or mortality (4). Inflammation is associated with both cardiac disease and depression and is a plausible physiological link between depression and coronary heart disease. Cross-sectional studies have demonstrated an association between depression and inflammation in healthy subjects (5–9) and in cardiac patients (10, 11), but relatively little is known about the directionality of the association (i.e., whether depression causes inflammation or vice versa).

Previous studies on the direction of the association between depression and inflammation have yielded conflicting results. Stewart and colleagues (12) examined the directionality of the relationship in otherwise healthy sub-

jects. They found that depressive symptoms as measured with the Beck Depression Inventory-II significantly predicted interleukin-6 (IL-6) levels after 6 years of follow-up, whereas inflammation did not predict depressive symptom scores at follow-up, suggesting that depression leads to an up-regulation of IL-6 levels. However, the Whitehall study came to the opposite conclusion. In over 3,000 British civil servants followed for almost 12 years, Gimeno and colleagues found that inflammation preceded depressive symptoms, whereas depressive symptoms did not predict inflammation (13).

To our knowledge, whether depressive symptoms are the cause or result of inflammation has not been evaluated in patients with cardiovascular disease. We therefore set out to evaluate the prospective association between depressive symptoms and inflammation using repeated measurements of depressive symptoms and inflammation in patients with stable coronary heart disease. We evalu-

This article is featured in this month's AJP [Audio](#), is discussed in an editorial by Dr. Schroeder (p. 876), is the subject of a [CME](#) course (p. 1005), and is an article that provides [Clinical Guidance](#) (p. 920)

ated whether depressive symptoms (assessed annually for 6 years) were associated with higher levels of subsequent inflammation and vice versa. In addition, we evaluated the role of health behaviors in mediating the association between depression and inflammation.

Method

Design and Participants

The Heart and Soul Study is an ongoing prospective cohort study of psychosocial factors and health outcomes in patients with coronary heart disease. Its methods have been described previously (14). Briefly, 1,024 outpatients with stable coronary heart disease were recruited and completed a baseline examination between September 2000 and December 2002. Following the baseline examination, patients received annual telephone calls for assessment of depressive symptoms. Between September 2005 and December 2007, 667 participants (80% of the 829 survivors) completed a 5-year follow-up examination that included measures of inflammation. The study protocol was approved by the appropriate institutional review boards, and all participants provided written informed consent.

Depressive Symptoms

Depressive symptoms were assessed annually for 6 years by using the 9-item Patient Health Questionnaire, a self-report instrument that measures the frequency of depressive symptoms corresponding to the nine DSM-IV criteria for depression (15). A paper-and-pencil version of the questionnaire was administered at the baseline examination (year 0), telephone versions were administered after 1, 2, 3, and 4 years of follow-up, and a paper-and-pencil version was again administered after 5 years of follow-up. Of the 667 participants who were examined at 5 years, 640 completed five or more interviews, 23 (3.4%) completed four interviews, three (0.4%) completed three interviews, and one (0.1%) completed two interviews.

At each assessment, participants were asked to indicate the frequency of experiencing each depressive symptom during the last 2 weeks. Each of the nine symptoms was scored as 0 (not at all), 1 (on several days), 2 (more than half the days), or 3 (nearly every day), with total scores ranging from 0 to 27 (16). The Patient Health Questionnaire has demonstrated excellent validity when compared with a mental health interview for depression in patients with coronary heart disease (17, 18). Telephone and in-person assessments yield similar results (19). As a summary measure of depressive symptoms, we calculated the mean score for each participant as the sum of the annual questionnaire scores divided by the number of interviews completed. We also created a categorical variable by defining "depressive symptoms" as a score of 10 or higher on the Patient Health Questionnaire. We used this to group the participants into three categories: depressive symptoms at two or more interviews, depressive symptoms at one interview, or no depressive symptoms. We chose these groups for analysis because further divisions would have yielded too few participants in each category.

Inflammatory Biomarkers

Fasting blood samples were obtained at baseline and after 5 years of follow-up. Levels of high-sensitivity C-reactive protein (hsCRP), IL-6, and fibrinogen were determined from plasma and serum samples. The laboratory technicians were blinded to the depression status of the participants.

A highly sensitive CRP assay was performed with a BN II nephelometer (Dade-Behring, Newark, Del.). Interassay coefficients of variation were 1.66%–5.32%. IL-6 was measured by using the

Millipore Milliplex Map kit (Millipore, Billerica, Mass.), with interassay coefficients of variation from 6.3% to 11.6%. Concentrations of serum fibrinogen were determined by the Claus assay with coefficients of variation less than 3%. We log-transformed the hsCRP and IL-6 levels because they were not normally distributed, and we verified that the transformation resulted in normal distributions. We also created three separate dichotomous variables for IL-6, hsCRP, and fibrinogen, defining a priori a high level as one in the highest quartile. For IL-6 a high level was defined as above 5.40 pg/ml, for hsCRP a high level was one above 3.48 mg/liter, and a high fibrinogen level was defined as above 420 mg/dl.

Other Assessments

We recorded self-reported age, gender, ethnicity, education, and medical history at baseline and at the 5-year examination. In addition, we assessed health behaviors known to be associated with inflammation, such as smoking status, physical activity, and body mass index (BMI) (20, 21). To assess physical activity, we asked, "Which of the following statements best describes how physically active you have been during the last month, that is, done activities such as 15–20 minutes of brisk walking, swimming, general conditioning, or recreational sports?" Participants responded by choosing one of the six following categories: not at all active, a little active (one or two times per month), fairly active (three or four times per month), quite active (one or two times per week), very active (three or four times per week), or extremely active (five or more times per week). Self-report of physical activity has been shown to be valid, accurate, and reliable (22–25). Physical inactivity was defined as "not at all active" or "a little active." Height and weight were measured and used to calculate BMI (weight in kilograms divided by the square of height in meters). Alcohol consumption was measured with the AUDIT-C self-report questionnaire (26). Left ventricular ejection fraction was assessed by means of two-dimensional echocardiography. High-density lipoprotein (HDL) levels were measured from fasting venous blood samples, and non-HDL cholesterol was calculated as total cholesterol minus HDL cholesterol. Participants were asked to bring all of their medication bottles to the study appointment, and all current medications were recorded. Medications were categorized by using Epocrates Rx (Epocrates, San Mateo, Calif.).

Statistical Analyses

The goal of this study was to determine the directionality of the depression-inflammation relationship. We used general linear models to compare mean levels of each marker across three groups: participants who were not depressed at any interview (having a score below 10 on the Patient Health Questionnaire at all interviews), participants who reported depressive symptoms (a score of 10 or higher) at one interview, and those who reported significant depressive symptoms at two or more interviews.

To further evaluate the association between Patient Health Questionnaire score and levels of inflammation, we used multivariate analysis of variance adjusted for other patient characteristics associated with depressive symptoms (age, gender, education, race, aspirin use, history of diabetes, myocardial infarction, and congestive heart failure) and health behaviors (physical activity, smoking, and BMI). In addition, we evaluated change in inflammation over 5 years across the three subgroups. Finally, we used multivariate analysis of covariance (MANCOVA) to evaluate the effect of depressive symptoms on all three measures of inflammation as a single dependent variable, adjusted for the baseline level of inflammation. We also used MANCOVA to evaluate the effect of inflammation on subsequent depressive symptoms (as a single dependent variable), adjusted for the baseline level of depressive symptoms. Analyses were performed by using SAS 9.2 (SAS Institute, Cary, N.C.).

Results

Characteristics of Participants

As compared with the 162 patients who were alive and did not complete the 5-year follow-up examination, the 667 participants who completed the exam were older (mean age=66 years, SD=10, versus mean=64 years, SD=12; $t=-2.09$, $df=827$, $p=0.04$) and had fewer baseline depressive symptoms as indicated by scores on the Patient Health Questionnaire (mean=4.75, SD=5.26, versus mean=6.77, SD=5.84; $t=4.29$, $df=827$, $p<0.01$). Participants who completed the exam also had lower log-transformed baseline hsCRP levels (mg/liter) than those who did not complete the 5-year exam (mean=0.57, SD=1.29, versus mean=0.85, SD=1.32; $t=2.48$, $df=795$, $p=0.01$). Baseline levels of IL-6 and fibrinogen were similar in the patients who did and did not complete the 5-year examination ($p>0.10$ in both cases).

Of the 667 participants who completed the 5-year examination, 138 (21%) had depressive symptoms (i.e., a score of 10 or higher on the Patient Health Questionnaire) at two or more interviews, 86 (13%) had depressive symptoms at one interview, and 443 (66%) had no significant depressive symptoms (a score less than 10 on the Patient Health Questionnaire at all interviews). As compared to participants without significant depressive symptoms, those with depressive symptoms at any interview were younger and less likely to be male, to be white, or to have graduated from high school (Table 1). They were more likely to have a history of diabetes, myocardial infarction, or congestive heart failure and had higher BMI values. Participants with depressive symptoms were less likely to use aspirin and more likely to smoke and to be physically inactive. The three groups had similar levels of hypertension, cardiac disease severity, cardiac risk factors, and use of cardioprotective medications.

Presence of Depressive Symptoms as Predictor of Subsequent Inflammation

MANCOVAs evaluating the effect of depression on subsequent inflammation showed that depressive symptoms predicted subsequent inflammation in an unadjusted analysis ($F=2.56$, $df=6$, 1304, $p=0.02$) and after adjustment for age, gender, education, race, history of diabetes, myocardial infarction, congestive heart failure, aspirin use, and baseline levels of inflammatory markers ($F=2.15$, $df=6$, 1182, $p<0.05$). This association was no longer significant after adjustment for health behaviors ($F=1.74$, $df=6$, 1128, $p=0.11$).

Across the three groups, greater depressive symptoms were associated with higher subsequent log-transformed levels of IL-6 and hsCRP, and they were nonsignificantly associated with higher levels of fibrinogen (Table 2). Depressive symptoms remained associated with subsequent levels of IL-6 and were marginally related to levels of fibrinogen but were not associated with hsCRP, after adjustment for age, gender, education, race, history of diabetes,

myocardial infarction, congestive heart failure, and aspirin use (Table 2). However, after further adjustment for health behaviors (physical activity, smoking, and BMI), depressive symptoms were no longer associated with any inflammation index. When we evaluated the multivariable-adjusted mean change in levels of inflammatory markers, depressive symptoms did not predict statistically significant changes in IL-6, hsCRP, or fibrinogen (Table 3).

When we analyzed depressive symptoms as a continuous variable, the average score on the Patient Health Questionnaire across the annual assessments predicted subsequent log-transformed levels of IL-6 ($\beta=0.102$, $p=0.009$) and hsCRP ($\beta=0.121$, $p=0.002$) but not the level of fibrinogen ($\beta=0.058$, $p=0.13$). Again, this association was no longer significant after adjustment for health behaviors (log IL-6: $\beta=0.038$, $p=0.36$; hsCRP: $\beta=0.018$, $p=0.67$; fibrinogen: $\beta=0.018$, $p=0.68$).

When inflammation was evaluated as a dichotomous variable, the proportions of participants with levels of inflammatory markers in the highest quartile were 22% to 24% in those without depression at any interview, 23% to 28% in those with depressive symptoms at one interview, and 30% to 35% in patients with depressive symptoms at two or more interviews (Figure 1).

Inflammation as Predictor of Subsequent Depressive Symptoms

MANCOVAs revealed no effect of inflammation on subsequent depression in unadjusted analyses ($F=1.37$, $df=6$, 1256, $p=0.22$) or after adjustment for age, gender, education, race, history of diabetes, myocardial infarction, congestive heart failure, aspirin use, and baseline depressive symptoms ($F=0.65$, $df=6$, 1224, $p=0.69$). In addition, baseline levels of inflammatory markers were not associated with subsequent depressive symptoms (Table 4). As compared with participants who had significant depressive symptoms at two or more annual assessments, those without depressive symptoms had similar baseline levels of log IL-6, log hsCRP, and fibrinogen.

Discussion

The aim of this study was to examine the directionality of the depression-inflammation relationship in a group of patients with stable coronary heart disease. The rate of depressive symptoms was consistent with the rate in a previous study (27): 34% of the participants had a score of 10 or higher on the Patient Health Questionnaire at one or more time points. We found that depressive symptoms were associated with higher subsequent levels of inflammation, whereas baseline levels of inflammation did not predict subsequent depressive symptoms. The association between depressive symptoms and subsequent inflammation was eliminated after adjustment for health behaviors associated with inflammation—physical inactivity, smoking, and higher BMI. Taken together, these findings suggest that depression may lead to inflammation through

TABLE 1. Baseline Characteristics of 667 Patients With Coronary Heart Disease, by Depressive Symptoms Over 5 Years^a

Variable	Patients With No Depressive Symptoms at Any Interview (N=443 ^b)		Patients With Depressive Symptoms, Defined as Score ≥10 on Patient Health Questionnaire				Analysis		
			Depressive Symptoms at One Interview (N=86 ^b)		Depressive Symptoms at Two or More Interviews (N=138 ^b)				
	Mean	SD	Mean	SD	Mean	SD	F	df	p
Demographic characteristics									
Age (years)	72.8	9.2	68.6	12.0	66.3	11.0	24.26	2, 661	<0.01
	N	%	N	%	N	%	χ^2	df	p
Male	381	86	62	72	106	77	13.18	2	<0.01
White	277	63	42	49	79	57	6.03	2	0.05
High school graduate	402	91	70	81	112	81	13.63	2	<0.01
Comorbid conditions									
Hypertension	324	74	65	77	110	80	2.55	2	0.28
Myocardial infarction	205	47	53	63	70	51	7.66	2	0.02
Congestive heart failure	68	16	17	20	42	31	15.56	2	<0.01
Diabetes mellitus	122	28	35	41	35	26	7.12	2	0.03
Medication use									
Aspirin	338	76	58	67	86	62	11.40	2	<0.01
Beta-blocker	300	68	62	72	91	66	0.94	2	0.62
Renin-angiotensin system inhibitor	298	67	55	64	85	62	1.63	2	0.44
Statin	123	28	20	23	26	19	4.66	2	0.10
Health behaviors									
Regular alcohol use	132	30	19	23	32	24	3.24	2	0.20
Current smoking	42	10	13	16	37	27	25.81	2	<0.01
Physical inactivity	140	32	41	49	82	60	38.43	2	<0.01
	Mean	SD	Mean	SD	Mean	SD	F	df	p
Body mass index (kg/m ²)	28.1	5.0	29.8	6.0	29.6	7.0	5.59	2, 663	<0.01
Cardiac disease severity and risk factors									
Left ventricular ejection fraction	0.62	0.11	0.63	0.11	0.60	0.13	1.43	2, 654	<0.01
LDL cholesterol (mg/dl)	93.7	34.2	98.0	28.6	95.0	32.9	0.62	2, 653	0.54
HDL cholesterol (mg/dl)	47.5	14.8	47.3	18.6	45.6	14.3	0.75	2, 663	<0.01
Non-HDL cholesterol	115.7	38.9	124.0	34.1	120.8	37.0	2.28	2, 663	0.10

^a Depressive symptoms were assessed at baseline and annually for the next 5 years.

^b Total number varied because data on some variables were not available for all participants.

poor health behaviors, but inflammation does not lead to depression in patients with coronary heart disease.

There have been only a few studies regarding the directionality of the depression-inflammation relationship, and to our knowledge, this is the first study on this subject in a cardiac population. We also believe this to be the first study evaluating the association of depressive symptoms over time with subsequent inflammation. Our results extend the findings of Stewart and colleagues (12), who found that depression predicted high levels of IL-6, whereas high levels of IL-6 did not predict depression. However, our results differ from those of Gimeno and colleagues, who reported that CRP and IL-6 levels were predictive of subsequent depressive symptoms, but not vice versa, in the Whitehall II study (13).

One possible explanation for this discrepancy is that the Whitehall II study used a different measure of depressive symptoms. Their assessment was based on four items from the General Health Questionnaire (thinking of yourself as a worthless person, feeling that life is entirely hopeless, feeling that life is not worth living, and finding times when you could not do anything because your nerves

were too bad) and did not include measures of sleep, appetite, concentration, energy, suicidal thoughts, or depressed mood. In contrast, we administered the Patient Health Questionnaire, which was specifically designed to assess the nine symptoms of depression. Another possible explanation for the difference in findings is the difference between study populations. The association between depressive symptoms and inflammation in the general population may differ from the relationship in patients with established coronary heart disease.

It is interesting that our results show that depressive symptoms predicted high levels of hsCRP and IL-6 but not fibrinogen. A possible explanation could be that hsCRP and IL-6 are more specific for the underlying inflammation process in stable patients with coronary heart disease. In contrast to hsCRP and IL-6, which are both markers of inflammation, fibrinogen not only reflects inflammation but also is a blood coagulation factor (28), which could explain why we did not find a prospective association between depression and fibrinogen.

We also found that patients with depressive symptoms at two or more interviews had higher levels of inflamma-

TABLE 2. Levels of Inflammatory Markers at 5-Year Follow-Up in Patients With Coronary Heart Disease, by Depressive Symptoms Over 5 Years^a

Inflammatory Marker and Model ^b	Level of Inflammatory Marker at 5-Year Follow-Up						Analysis		
	Patients With No Depressive Symptoms at Any Interview (N=443)		Patients With Depressive Symptoms, Defined as Score ≥ 10 on Patient Health Questionnaire						
	Mean	SD/SE ^c	Mean	SD/SE ^c	Mean	SD/SE ^c	F	df	p
Interleukin-6, log-transformed (pg/ml)									
Unadjusted	1.19	0.66	1.19	0.71	1.38	0.71	4.36	2, 658	0.01
Model 1	1.13	0.06	1.34	0.08	1.51	0.07	4.46	2, 631	0.01
Model 2	1.40	0.06	1.38	0.08	1.52	0.70	1.91	2, 602	0.15
High-sensitivity C-reactive protein, log-transformed (mg/liter)									
Unadjusted	0.34	1.14	0.58	1.30	0.70	1.30	5.12	2, 658	<0.01
Model 1	0.70	0.11	0.88	0.15	0.90	0.12	1.78	2, 631	0.17
Model 2	0.80	0.12	0.90	0.16	0.91	0.13	0.45	2, 602	0.64
Fibrinogen (mg/dl)									
Unadjusted	371	79	370	87	391	102	2.87	2, 659	0.06
Model 1	385	8	381	11	404	9	2.50	2, 632	0.08
Model 2	393	9	386	12	408	10	1.80	2, 603	0.17

^a Depressive symptoms were assessed at baseline and annually for the next 5 years.

^b Model 1: adjusted for age, gender, education, race, history of diabetes, myocardial infarction, congestive heart failure, and aspirin use. Model 2: adjusted for all of the preceding variables plus physical activity, current smoking, and body mass index.

^c Unadjusted values use SD, and adjusted values use SE.

TABLE 3. Change in Inflammatory Marker Levels Over 5 Years in Patients With Coronary Heart Disease, by Depressive Symptoms Over 5 Years^a

Inflammatory Marker and Model ^b	Change in Level of Inflammatory Marker From Baseline to Year 5						Analysis		
	Patients With No Depressive Symptoms at Any Interview (N=443)		Patients With Depressive Symptoms, Defined as Score ≥ 10 on Patient Health Questionnaire						
	Mean	SD/SE ^c	Mean	SD/SE ^c	Mean	SD/SE ^c	F	df	p
Interleukin-6, log-transformed (pg/ml)									
Unadjusted	1.24	2.83	1.30	2.82	1.80	3.14	1.87	2, 628	0.16
Model 1	1.45	0.26	1.60	0.35	1.95	0.30	1.33	2, 602	0.26
Model 2	1.43	0.30	1.54	0.39	1.92	0.33	1.11	2, 574	0.33
High-sensitivity C-reactive protein, log-transformed (mg/liter)									
Unadjusted	-0.54	7.74	0.98	12.38	0.26	13.28	1.00	2, 629	0.37
Model 1	-0.85	0.89	0.85	1.23	0.10	1.03	1.12	2, 603	0.33
Model 2	-1.48	1.04	0.57	1.36	-0.18	1.14	1.54	2, 575	0.22
Fibrinogen (mg/dl)									
Unadjusted	-13.36	81.72	-16.68	80.52	7.06	102.64	3.10	2, 626	0.05
Model 1	-14.22	7.85	-19.35	11.05	5.07	9.00	2.63	2, 600	0.07
Model 2	-13.67	9.04	-17.13	12.07	7.21	9.85	2.66	2, 573	0.07


^a Depressive symptoms were assessed at baseline and annually for the next 5 years.

^b Model 1: adjusted for age, gender, education, race, history of diabetes, myocardial infarction, congestive heart failure, and aspirin use. Model 2: adjusted for all of the preceding variables plus physical activity, current smoking, and body mass index.

^c Unadjusted values use SD, and adjusted values use SE.

tion at follow-up than patients with depressive symptoms at one interview. To the extent that depressive symptoms at two or more interviews represented chronic or recurrent depression, our findings suggest that persistent depression may have greater effects on inflammation than a

single episode of depression. Consistent with these findings are the results of Hamer and colleagues (29), who found that in a group of 3,609 aging subjects, participants with depressive symptoms at two time points had higher levels of CRP and fibrinogen than those with depressive

FIGURE 1. Proportion of Patients With Coronary Heart Disease Who Had High Levels of Inflammatory Markers at 5-Year Follow-Up, by Depressive Symptoms Over 5 Years^a

^a Inflammatory markers were measured at baseline and at the 5-year follow-up assessment. Depressive symptoms were assessed with the nine-item Patient Health Questionnaire at baseline and annually for the next 5 years.

^b Significant difference among groups ($\chi^2=8.45$, $df=2$, $p=0.01$).

^c Significant difference among groups ($\chi^2=5.96$, $df=2$, $p=0.05$).

symptoms at one time point. In addition, Kaptein and colleagues (30) showed that patients with chronic depressive symptoms following myocardial infarction were at higher risk for having new cardiovascular events than those whose depressive symptoms resolved. Taken together, the findings suggest that the duration of depressive symptoms may influence cardiac health.

The prospective association of depression with inflammation was no longer significant after adjustment for health behaviors (physical inactivity, BMI, and smoking). Although our results cannot determine the direction of the association between depression and health behaviors, this raises the possibility that helping depressed cardiac patients improve these behaviors could potentially reduce inflammation. These findings are further supported by a longitudinal community-based study in which Matthews and colleagues (31) investigated the directionality of the depression-inflammation relationship among 1,781 premenopausal and early perimenopausal women who were free of cardiac disease at baseline. They found that depression, as measured with the Center for Epidemiologic Studies Depression Scale, was associated with higher CRP levels at follow-up. Similar to our results, this association was no longer significant after adjustment for a range of covariates including health behaviors. In addition, Hamer and colleagues (29) found that weight change, waist circumference, current smoking, alcohol use, and especially physical activity were significant mediators in the depression-inflammation relationship. Finally, Dod and colleagues (32) showed in a group of nonsmoking patients

with stable coronary heart disease that a combination of intensive exercise and dietary changes significantly lowered levels of IL-6 and CRP, suggesting that physical inactivity and BMI may influence inflammation levels.

Several strengths can be attributed to this study. First, the annual assessments of depressive symptoms and medical health status presented us with the opportunity to assess the direction of this association. In addition, biological and behavioral mediators were carefully assessed at baseline and after 5 years of follow-up. However, there are also several limitations. This study focused on outpatients with stable coronary heart disease. Our results may therefore not apply to healthy participants or to patients with acute coronary syndromes. Furthermore, the study group mostly consisted of older men, so these results may not be generalizable to either women or younger men. Finally, 20% (162 of 829) of the surviving participants did not complete the 5-year follow-up examination. However, these participants were younger and had worse depression scores than those who completed the examination, so including them would probably have strengthened the association between depression and inflammation.

In conclusion, we found no evidence of a bidirectional relationship between depression and inflammation. Depression was prospectively associated with IL-6 and hsCRP, but not vice versa. This prospective association was no longer significant after adjustment for physical inactivity, BMI, and smoking. These findings raise the possibility that helping depressed cardiac patients improve health behaviors could reduce inflammation.

TABLE 4. Baseline Levels of Inflammatory Markers in Patients With Coronary Heart Disease, by Depressive Symptoms Over 5 Years^a

Inflammatory Marker and Model ^b	Baseline Level of Inflammatory Marker						Analysis		
	Patients With No Depressive Symptoms at Any Interview (N=443)		Patients With Depressive Symptoms, Defined as Score ≥ 10 on Patient Health Questionnaire						
	Mean	SD/SE ^c	Mean	SD/SE ^c	Mean	SD/SE ^c	F	df	p
Interleukin-6, log-transformed (pg/ml)									
Unadjusted	0.84	0.66	0.85	0.66	0.92	0.73	0.66	2, 633	0.52
Model 1	0.91	0.06	0.94	0.08	1.06	0.07	2.15	2, 618	0.12
Model 2	1.05	0.07	1.04	0.08	1.05	0.07	0.02	2, 612	0.98
High-sensitivity C-reactive protein, log-transformed (mg/liter)									
Unadjusted	0.49	1.26	0.66	1.28	0.76	1.37	2.45	2, 634	0.09
Model 1	0.94	0.12	1.00	0.16	1.13	0.14	0.98	2, 619	0.37
Model 2	1.14	0.13	1.12	0.16	1.09	0.14	0.05	2, 613	0.95
Fibrinogen (mg/dl)									
Unadjusted	384	82	387	78	383	92	0.05	2, 630	0.95
Model 1	400	8	399	11	401	9	0.02	2, 615	0.99
Model 2	414	9	409	11	402	9	0.91	2, 609	0.40

^a Depressive symptoms were assessed at baseline and annually for the next 5 years.

^b Model 1: adjusted for baseline age, gender, education, race, history of diabetes, myocardial infarction, congestive heart failure, and aspirin use. Model 2: adjusted for all of the preceding variables plus baseline physical activity, current smoking, and body mass index.

^c Unadjusted values use SD, and adjusted values use SE.

Received Aug. 16, 2010; revisions received Dec. 20, 2010, and March 26, 2011; accepted April 25, 2011 (doi: 10.1176/appi.ajp.2011.10081163). From the Center of Research on Psychology in Somatic Diseases, Tilburg University, Tilburg, the Netherlands; the Department of Psychiatry, University Medical Center, University of Groningen, Groningen, the Netherlands; the Department of Psychiatry/EMGO Institute, University Medical Center, Vrije Universiteit, Amsterdam; the Section of General Internal Medicine, VA Medical Center, San Francisco; and the Department of Medicine, University of California, San Francisco. Address correspondence to Ms. Duivis (h.e.duivis@uvt.nl).

All authors report no financial relationships with commercial interests.

The Heart and Soul Study was funded by the Department of Veterans Affairs; the National Heart, Lung, and Blood Institute (grant R01 HL-079235); the American Federation for Aging Research (Paul Beeson Scholars Program); the Robert Wood Johnson Foundation (Generalist Physician Faculty Scholars Program); and the Ischemia Research and Education Foundation. Dr. de Jonge was supported by a Vidi grant from the Dutch Medical Research Council (grant 016.086.397). Dr. Cohen was supported by NCCR/OD UCSF-CITSI grant KL2 RR-024130 from the NIH Division of Research Resources. The funding organizations had no role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; or preparation, review, or approval of the manuscript.

References

- Thombs BD, Bass EB, Ford DE, Stewart KJ, Tsilidis KK, Patel U, Fauerbach JA, Bush DE, Ziegelstein RC: Prevalence of depression in survivors of acute myocardial infarction. *J Gen Intern Med* 2006; 21:30–38
- Wells KB, Rogers W, Burnam MA, Camp P: Course of depression in patients with hypertension, myocardial infarction, or insulin-dependent diabetes. *Am J Psychiatry* 1993; 150:632–638
- van Melle JP, de Jonge P, Spijkerman TA, Tijssen JG, Ormel J, van Veldhuisen DJ, van den Brink RH, van den Berg MP: Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. *Psychosom Med* 2004; 66:814–822
- de Jonge P, Rosmalen JG, Kema IP, Doornbos B, van Melle JP, Pouwer F, Kupper N: Psychophysiological biomarkers explaining the association between depression and prognosis in coronary artery patients: a critical review of the literature. *Neurosci Biobehav Rev* 2010; 35:84–90
- Danner M, Kasl SV, Abramson JL, Vaccarino V: Association between depression and elevated C-reactive protein. *Psychosom Med* 2003; 65:347–356
- Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctot KL: A meta-analysis of cytokines in major depression. *Biol Psychiatry* 2010; 67:446–457
- Elovainio M, Aalto AM, Kivimaki M, Pirkola S, Sundvall J, Ronnanen A: Depression and C-reactive protein: population-based Health 2000 Study. *Psychosom Med* 2009; 71:423–430
- Ford DE, Erlinger TP: Depression and C-reactive protein in US adults: data from the Third National Health and Nutrition Examination Survey. *Arch Intern Med* 2004; 164:1010–1014
- Penninx BW, Kritchevsky SB, Yaffe K, Newman AB, Simonsick EM, Rubin S, Ferrucci L, Harris T, Pahor M: Inflammatory markers and depressed mood in older persons: results from the Health, Aging and Body Composition Study. *Biol Psychiatry* 2003; 54:566–572
- Bankier B, Barajas J, Martinez-Rumayor A, Januzzi JL: Association between major depressive disorder and C-reactive protein levels in stable coronary heart disease patients. *J Psychosom Res* 2009; 66:189–194
- Howren MB, Lamkin DM, Suls J: Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. *Psychosom Med* 2009; 71:171–186
- Stewart JC, Rand KL, Muldoon MF, Kamarck TW: A prospective evaluation of the directionality of the depression-inflammation relationship. *Brain Behav Immun* 2009; 23:936–944
- Gimeno D, Kivimaki M, Brunner EJ, Elovainio M, De Vogli R, Steptoe A, Kumari M, Lowe GD, Rumley A, Marmot MG, Ferrie JE: Associations of C-reactive protein and interleukin-6 with

- cognitive symptoms of depression: 12-year follow-up of the Whitehall II study. *Psychol Med* 2009; 39:413–423
14. Whooley MA, de Jonge P, Vittinghoff E, Otte C, Moos R, Carney RM, Ali S, Dowray S, Na B, Feldman MD, Schiller NB, Browner WS: Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. *JAMA* 2008; 300:2379–2388
 15. Spitzer RL, Kroenke K, Williams JB: Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study: Primary Care Evaluation of Mental Disorders Patient Health Questionnaire. *JAMA* 1999; 282:1737–1744
 16. Kroenke K, Spitzer RL, Williams JB: The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med* 2001; 16:606–613
 17. Stafford L, Berk M, Jackson HJ: Validity of the Hospital Anxiety and Depression Scale and Patient Health Questionnaire-9 to screen for depression in patients with coronary artery disease. *Gen Hosp Psychiatry* 2007; 29:417–424
 18. Thombs BD, Ziegelstein RC, Whooley MA: Optimizing detection of major depression among patients with coronary artery disease using the Patient Health Questionnaire: data from the Heart and Soul Study. *J Gen Intern Med* 2008; 23:2014–2017
 19. Pinto-Meza A, Serrano-Blanco A, Penarrubia MT, Blanco E, Haro JM: Assessing depression in primary care with the PHQ-9: can it be carried out over the telephone? *J Gen Intern Med* 2005; 20:738–742
 20. O'Connor M-F, Bower JE, Cho HJ, Creswell JD, Dimitrov S, Hamby ME, Hoyt MA, Martin JL, Robles TF, Sloan EK, Thomas KS, Irwin MR: To assess, to control, to exclude: effects of biobehavioral factors on circulating inflammatory markers. *Brain Behav Immun* 2009; 23:887–897
 21. Frost-Pineda K, Liang Q, Liu J, Rimmer L, Jin Y, Feng S, Kapur S, Mendes P, Roethig H, Sarkar M: Biomarkers of potential harm among adult smokers and nonsmokers in the Total Exposure Study. *Nicotine Tob Res* 2011; 13:182–193
 22. Aadahl M, Kjaer M, Kristensen JH, Mollerup B, Jorgensen T: Self-reported physical activity compared with maximal oxygen uptake in adults. *Eur J Cardiovasc Prev Rehabil* 2007; 14:422–428
 23. Ainsworth BE, Jacobs DR Jr, Leon AS: Validity and reliability of self-reported physical activity status: the Lipid Research Clinics questionnaire. *Med Sci Sports Exerc* 1993; 25:92–98
 24. Bowles HR, FitzGerald SJ, Morrow JR Jr, Jackson AW, Blair SN: Construct validity of self-reported historical physical activity. *Am J Epidemiol* 2004; 160:279–286
 25. Kurtze N, Rangul V, Hustvedt BE, Flanders WD: Reliability and validity of self-reported physical activity in the Nord-Trondelag Health Study: HUNT 1. *Scand J Public Health* 2008; 36:52–61
 26. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA: The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking: Ambulatory Care Quality Improvement Project (ACQUIP) Alcohol Use Disorders Identification Test. *Arch Intern Med* 1998; 158:1789–1795
 27. Blumenthal JA: Depression and coronary heart disease: association and implications for treatment. *Cleve Clin J Med* 2008; 75(suppl 2):S48–S53
 28. Ridker PM, Genest J, Libby P: Risk factors for atherosclerotic disease, in *Heart Disease: A Textbook of Cardiovascular Medicine*, 6th ed. Edited by Braunwald E, Zipes DP, Libby P. Philadelphia, WB Saunders, 2001, pp 1010–1039
 29. Hamer M, Molloy GJ, de Oliveira C, Demakakos P: Persistent depressive symptomatology and inflammation: to what extent do health behaviours and weight control mediate this relationship? *Brain Behav Immun* 2009; 23:413–418
 30. Kaptein KI, de Jonge P, van den Brink RH, Korf J: Course of depressive symptoms after myocardial infarction and cardiac prognosis: a latent class analysis. *Psychosom Med* 2006; 68:662–668
 31. Matthews KA, Schott LL, Bromberger JT, Cyranowski JM, Everson-Rose SA, Sowers M: Are there bi-directional associations between depressive symptoms and C-reactive protein in mid-life women? *Brain Behav Immun* 2010; 24:96–101
 32. Dod HS, Bhardwaj R, Sajja V, Weidner G, Hobbs GR, Konat GW, Manivannan S, Gharib W, Warden BE, Nanda NC, Beto RJ, Ornish D, Jain AC: Effect of intensive lifestyle changes on endothelial function and on inflammatory markers of atherosclerosis. *Am J Cardiol* 2010; 105:362–367

Clinical Guidance: Depression, Smoking, and Heart Disease

Depression was associated with increased inflammation as measured by elevated levels of interleukin-6 and high-sensitivity C-reactive protein in patients with coronary heart disease from the Heart and Soul Study, report Duivis et al. The effect was accounted for by the increased body mass index and cigarette smoking associated with depression. Schroeder points out in an editorial (p. 876) that effective treatments for smoking cessation do not interfere with treatment of depression or cause suicide. Treatment of both smoking and depression with bupropion and referral to a “quitline” are possible strategies.